Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

NVS

19 posts
NNovartis
Novartis AG logo
Read More

FDA Approval for LAMPRENE issued to NOVARTIS

  • 2026-11-03
What this release says The FDA approved a labeling change (SUPPL-15) to Novartis’s NDA 019500 for LAMPRENE, with…
NNovartis
In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)
Read More

Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback

  • 2026-10-16
The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care…
NNovartis
Zacks Investment Research
Read More

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

  • 2026-10-08
Novartis NVS received a key regulatory win for Rhapsido (remibrutinib) in the United States, with the FDA approving…
NNovartis
DIA
Read More

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

  • 2026-10-03
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations. Novartis…
NNovartis
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Read More

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

  • 2026-09-08
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent…
NNovartis
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Read More

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

  • 2026-09-07
Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide…
NNovartis
Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks
Read More

Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks

  • 2026-09-07
Novartis AG (NYSE:NVS) could be staring at a $3 billion annual peak-sales opportunity in multiple sclerosis (MS) if…
NNovartis
Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion
Read More

Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion

  • 2026-09-07
Novartis NVS, the Swiss pharmaceutical giant, traded at $159.99 Monday after pelacarsen flopped in a pivotal Phase 3…
NNovartis
European Markets Dip Amid Oil Price Surge and Novartis (NVS) Sto
Read More

European Markets Dip Amid Oil Price Surge and Novartis (NVS) Sto

  • 2026-09-07
On September 07, 2026, European stock markets experienced pressure due to rising oil prices and a significant drop…
NNovartis
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Read More

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

  • 2026-09-07
Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide…
NNovartis
Novartis Just Lost a Potential $6 Billion Drug Opportunity
Read More

Novartis Just Lost a Potential $6 Billion Drug Opportunity

  • 2026-09-07
Novartis AG (NVS, Financials) has received a sobering reminder of how quickly billions of dollars in prospective medicine…
BBasel
Novartis (NVS)’s Latest Basel Move Signals a Shift in Strategic Priorities
Read More

Novartis (NVS)’s Latest Basel Move Signals a Shift in Strategic Priorities

  • 2026-09-04
Novartis AG (NYSE:NVS) could cut around 130 jobs in Switzerland as it relocates laboratory activities and ends small-scale…
Switzerland
www.europesays.com